WO2001032205A1 - Preventifs muqueux contre la mastite - Google Patents

Preventifs muqueux contre la mastite Download PDF

Info

Publication number
WO2001032205A1
WO2001032205A1 PCT/JP2000/007445 JP0007445W WO0132205A1 WO 2001032205 A1 WO2001032205 A1 WO 2001032205A1 JP 0007445 W JP0007445 W JP 0007445W WO 0132205 A1 WO0132205 A1 WO 0132205A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cell
mastitis
inactivated
preparation
Prior art date
Application number
PCT/JP2000/007445
Other languages
English (en)
Japanese (ja)
Inventor
Takuya Koji
Takuji Seo
Toshikatsu Hayashi
Original Assignee
Takeda Schering-Plough Animal Health K.K.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Schering-Plough Animal Health K.K. filed Critical Takeda Schering-Plough Animal Health K.K.
Priority to AU79564/00A priority Critical patent/AU7956400A/en
Publication of WO2001032205A1 publication Critical patent/WO2001032205A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine

Definitions

  • the present invention relates to an orally or nasally-administered mucosal preventive agent for mastitis, which is useful for preventing mastitis diseases such as cattle caused by bacterial infection, particularly to mammals such as livestock, and livestock containing the same. For feed.
  • Livestock such as cows, horses, sheep, goats, and pigs are fed by lactating pups after delivery.
  • mastitis develops due to bacterial infection of the breast. Mastitis has also been found to occur during the dry period before cows give birth.
  • the incidence of mastitis in cattle is particularly high, with 50% of dairy cows reported in Japan and the United States of America (Asato, Veterinary Society, 136, 27-36 (1993), Cul lor, Clinical Veterinary Medicine, Vol. 12, No. 1, pp. 17-27 (1994))
  • Mastitis in cattle is a clinical mastitis with hot sensation, pain, redness, and swelling, and these symptoms.
  • antibiotics eg, cloxacillin
  • cephalosporins eg, cefazolin
  • streptomycin oki Antibiotic ointments such as citetracycline and erythromycin
  • an intramammary injection of an antibiotic ointment is performed on the day of drying two months before delivery.
  • intramammary injection of antibiotic ointment and intramuscular administration of antibiotic injection are performed for several days. During the period of administration of the antibiotic and the suspension of the drug, milk cannot be sold due to legal regulations, so the economic loss is significant. Significant expenditures are also made on veterinarian rewards and medications needed for treatment.
  • the present invention provides a more practical preventive agent for mucosal mastitis in mammals by oral or nasal administration, that is, a far more effective preventive agent than previously known. That is, according to one aspect of the present invention, there is provided a mucosal vaccine for mammalian mastitis which is more practical and useful by the oral or nasal administration method.
  • S. filococcus aureus (hereinafter referred to as "S. aureus”), which is the causative agent of mammalian mastitis.
  • Oral or nasal administration of bacterial cells obtained by inactivating cultured bacterial cells such as "Reus") or lysed bacterial cells with an adjuvant is caused by S. aureus, etc.
  • the present inventors have found that the present invention has a preventive effect on mastitis, and have further studied based on these findings. As a result, the present invention has been completed.
  • a polysaccharide such as a mucopolysaccharide
  • an inactivated bacterial cell such as aoi membrane and cell wall
  • livestock containing an inactivated microbial cell or a bacterial cell elution-treated product containing a protein or a polysaccharide (mucopolysaccharide or the like) of an outer wall (aoi membrane, cell wall, etc.) of the microbial cell is used. Feed is provided.
  • Immunization by oral or nasal administration of the vaccine relies on the induction of secretory IgA (slgA) in the secretions. That is, the mucous membranes of the whole body, such as the mammary gland, gastrointestinal tract, and respiratory tract, are in direct contact with the outside world.
  • the defense mechanisms here include (1) non-specific defense mechanisms by lysozyme and lactoferrin, and (2) A protective mechanism by an immune reaction specifically corresponding to a specific foreign antigen can be mentioned.
  • the latter defense mechanism by the immune response is further divided into two groups: (2-1) local immune system (local immune system) and (2-2) systemic immune system (sys temic immune system). is there.
  • the local immune system is an immune system that involves immunoglobulin, an IgA that is produced and secreted from lymphocytes widely distributed in mucous membranes. It is often referred to as the mucosal immune system because it plays a major role in the immune response in the mucosal system of the whole body.
  • the systemic immunity mechanism is the immunity that is mainly carried out by IgG, which responds to foreign antigens that have invaded the living body by breaking specific and non-specific defense mechanisms on the mucosal surface, and lymphocytes associated therewith.
  • System In the case of mastitis, what is needed to prevent new infections is the nonspecific immune mechanisms described above and the slgA It is a membrane immune mechanism. When bacteria pass through the mucous membranes and invade the mammary gland tissue to establish infection, the IgG-mediated systemic immune system operates.
  • IgA is induced by antigen stimulation through the mucosal surface, and the process has been analyzed in the intestine of mammals.
  • Peyer's patches P.P.
  • IgA-inducing tissue For example, orally administered antigens that reach the intestinal tract are taken up by M cells, special epithelial cells that cover P.P. M cells have no antigen-presenting ability, and macrophage II dendritic cells located in the dome region below treat antigens as antigen-presenting cells and activate T lymphocytes.
  • IgA-producing progenitor B cells affected by antigen stimulation and activated T lymphocytes enter the circulatory system via mesenteric lymph nodes and thoracic ducts, and the mucous membrane includes not only the intestinal tract but also the respiratory system and mammary gland It is distributed in the eigenlayer. From the above, it is preferable to sensitize the mucosa directly to the mucous membrane via the oral or nasal route in order to activate the mucosal immune mechanism by IgA.
  • the bacterium that can be used for preparing the preparation for oral or nasal administration of the present invention is not particularly limited as long as it is a bacterium that is involved in mastitis.
  • Sexually active Sirophycoccus (Coagulase negative Staphylococci), Streptococcus agalactiae (Streptococcus agalactiae), Streptococcus' ice galactia (Streptococcus dysgalact iae), Streptococcus-uberis (Streptococcus uberisept) bovis), Enterococcus faecal is, Corynebacterium bovis, Actinomyces pyogenes, Escherichia coli and Klebsiella lemonella pneumoniae) And the like.
  • Bacteria for vaccine production can be obtained by culture.
  • the culture may be performed using either a known liquid medium or solid medium, and the medium and culture conditions may be appropriately selected so that the cells can be obtained efficiently.
  • a broth culture medium, a normal agar medium and the like can be mentioned.
  • the culture medium may be improved by adding milk whey or the like to increase the yield of cells or to increase the disease-causing property.
  • the cultivation may be carried out by culturing the target bacterium in a medium obtained by sterilizing the above-mentioned medium according to the usage thereof, and shaking or standing at 37T: for about 8 hours to 1 week, preferably for 20 to 48 hours.
  • the cells after culturing may be in a state of suspension in a culture solution.However, in order to perform the subsequent processing more efficiently, a known method such as centrifugal sedimentation, filtration or coagulation sedimentation from the culture after culturing is required. Preferably, the cells are recovered as a precipitate or a concentrate by the method described in (1).
  • the “inactivation” treatment in the “inactivated cell body” in the present invention refers to a treatment for losing the pathogenicity of bacteria, that is, infectivity. Specifically, it suffices to lose the proliferative ability, such as sterilization.
  • the inactivation of the cells can be achieved by a method of treating the cells with a weak acid such as formalin or acetic acid, a black form, a method of irradiating the cells with ultraviolet rays, a method of heating the cells, and the like.
  • a weak acid such as formalin or acetic acid
  • a black form a method of irradiating the cells with ultraviolet rays
  • a method of heating the cells and the like.
  • it is preferable to inactivate the cells by formalin treatment it is appropriate that formalin is allowed to act on the cells at a concentration of usually 0.2 to 1.0%.
  • a cell elution-treated product containing a cell outer wall protein or a polysaccharide refers to a treated product obtained by subjecting a cell to "a treatment for eluting at least a cell outer wall protein or a polysaccharide”. means.
  • the bacterial cell elution product in the present invention is prepared so as to contain at least the outer wall protein or polysaccharide of the bacterial cells, but may contain other bacterial cell components such as intracellular components in addition thereto.
  • the cells may be contained as they are.
  • "at least the cell outer wall protein or Is a treatment to elute polysaccharides ” is a treatment to release or elute at least all or part of the bacterial cell outer wall protein or polysaccharide from the cells.
  • Typical examples of this treatment include a heat treatment or a lysis treatment of the cells. It can also be achieved by the above-mentioned inactivation treatment.
  • the heat treatment is carried out by treating the cultured cells or a suspension thereof at 60 to 100, preferably 70 to 80, for 10 to 60 minutes, preferably for 20 to 30 minutes.
  • the processing conditions are appropriately selected according to the amount of the cells and the material and shape of the processing container in which the cells are placed and heated.
  • the lysis treatment is a treatment for dissolving or releasing at least a part of a protein or a polysaccharide (for example, mucopolysaccharide) of a cell wall, an outer membrane of a cell, and, for example, a lytic enzyme treatment or a physical crushing method.
  • Physical treatments such as (eg, ultrasonic crushing method) or a method of repeating freezing and thawing (freezing and thawing method) or a combination of these physical treatments.
  • autolysis of bacteria which can occur depending on the culture conditions, is also included in the lysis treatment.
  • the lytic enzyme may be any hydrolyzing enzyme that does not impair the antigenicity of the cell walls, outer membrane proteins or polysaccharides, and may be any of lysozyme, cellulase, achromopeptidase, and serratiopeptidase. (Trade name: DAISEN, manufactured by Takeda Pharmaceutical Co., Ltd.), and particularly, lysozyme is preferably used. Lysozyme should be made of readily available, commercially available egg white.
  • the lytic enzyme treatment may be performed according to a known method depending on the hydrolase to be used.If the cells are difficult to lyse, an anionic surfactant is particularly added after or simultaneously with the lytic enzyme treatment. Good.
  • the hydrophobic group is preferably an aliphatic hydrocarbon group or an aromatic hydrocarbon group
  • the hydrophilic group is a carboxylate (general formula: R'COONa)
  • the hydrophilic group is a sulfate.
  • R 2 0S0 3 Na hydrophilic group scan
  • a surfactant which is a sulfonate (general formula: R 2 S 0 3 Na or R 2 C 6 H 4 S 0 3 Na)
  • R 1 is C3 ⁇ 4 (CH 2 )
  • m On is 2 or more
  • R 2 represents a group represented by C (CH 2 ) hopefully(n represents an integer of 4 or more and 15 or less, preferably 7 or more and 11 or less
  • anionic surfactants those having excellent water-solubility and strong bacteriolysis in a temperature range in which the lytic enzyme can act, particularly in the vicinity of room temperature, are preferable, and they are easily available.
  • R'COONa As a compound represented by R'COONa, R 'is decanoic acid of CH 3 (CH 2 ) 8 or R 1 is CH 3 (CH 2 ) such as lauric acid 1Q are preferably used. Examples of the compounds represented by R 2 OS0 3 Na, sodium lauryl sulfate R z is CH 3 (CH 2) " And the like are preferably used. As the compound represented by R 2 S0 3 Na, R 2 is preferably sodium decanesulfonate of CH 3 (CH 2 ) 9 , and as the compound represented by R 2 C 6 H 4 S0 3 Na, Sodium laurylbenzenesulfonate wherein R 2 is CH 3 (CH 2 ) listenis preferably used.
  • Ultrasonic treatment in physical crushing method The crushing method may be performed by a known method using a commercially available ultrasonic generator.For example, a cell suspension is oscillated at 20 KHz and output at 200 W for 5 to 30 minutes. It is good to process to the extent.
  • the freeze-thawing method may be performed by a known method.For example, a method of freezing the cells at about 20 to 30 and then thawing at 30 to 40 to repeat the operation of thawing the cells is to destroy a part of the cells. No. Dehydration drying using an organic solvent such as acetone, heating vacuum drying, freeze drying, etc. may be performed, and a mechanical treatment used for crushing solids or powders may be added.
  • a known method of freezing the cells at about 20 to 30 and then thawing at 30 to 40 to repeat the operation of thawing the cells is to destroy a part of the cells.
  • No. Dehydration drying using an organic solvent such as acetone, heating vacuum drying, freeze drying, etc. may be performed, and a mechanical treatment used for crushing solids or powders may be added.
  • an inactivated cell a cell elution treatment containing the outer wall protein or polysaccharide of the cell, and a cell elution treatment containing the inactivated cell outer wall protein or the polysaccharide are included. And any one of them may be contained, and two or three of these may be contained. In such a case, by inactivating the cells as described above, some of the cells lose their growth ability or are sterilized. As a result, a part of the cells can be used as the product of the present invention as a cell-eluted product in which the cell outer wall protein or polysaccharide is eluted.
  • the solution containing the inactivated cells, the cell-eluted product containing the outer wall protein of the cells, or the polysaccharide prepared as described above can be directly orally or nasally administered to mammals, but is frozen or refrigerated. It is also possible to preserve it. Thaw it when necessary, and, if necessary, dilute it appropriately with water or the like, and then orally or nasally administer it to mammals such as livestock.
  • the powder may be dried and powdered by freeze-drying, dehydration-drying with acetone, or the like, and further appropriately diluted and prepared with starch or saccharide before administration.
  • Adjuvants include cholera toxin (cholera toxin, CT), Escherichia coli heat-labile exotoxin (heat-lab lile enterotoxin, LT) or non-toxic CT and LT derived from mutants excluding these virulences, or Examples include phosphoryl lipid A (monophosphoryl lipid A) and sahonin (Qui 1 laj a saponin).
  • the inactivated cell or the cell elution treated product containing the outer wall protein or polysaccharide of the cell described above has low toxicity and excellent safety in mammals.
  • Rat, mouse, guinea pig, hidge, goat, bush, ⁇ It can be used as a preventive agent for mastitis in mammals such as horses, horses, cats, dogs, monkeys, and humans (preferably, livestock such as horses, horses, sheep, goats, and bush).
  • a lysate or powder containing inactivated cells or a cell elution-treated product containing the outer wall protein or polysaccharide of the cells is used. It may be added to the feed and given.
  • the feed may be a compound feed, a compound feed for private use, or a cereal (corn, grain sorghum, barley, barley, oats, rye, brown rice, flour, kinako, etc.) which are generally commercially available as feeds for the above mammals.
  • a lysate containing inactivated cells or a cell lysate containing a cell surface protein or a polysaccharide containing a cell lysate containing a polysaccharide is manually or electrically sprayed (nebulizer 1) or the like. It can be sprayed into the nasal cavity.
  • Preparation of dried bacterial cell components coated with a coating agent such as a fatty acid such as decanoic acid or a physiologically acceptable fat-soluble substance such as hardened oil or fat, or an enteric polymer compound used in the production of enteric-coated preparations A lysate using an oil or fat and a surfactant may be used as a water-in-oil emulsion that is not dispersed in water, or may be prepared by applying a known formulation technique such as a liposome formulation. Of course, those preparations are only for oral administration Alternatively, it may be used for nasal administration.
  • the fat-soluble substance used as the coating agent examples include fatty acids such as decanoic acid (capric acid), stearic acid, lauric acid, and palmitic acid, and fats and oils such as hardened tallow or hardened soybean oil.
  • the coating with a fatty acid fat is performed by a known coating preparation technique, for example, by adding a solution of a fat-soluble substance to a bacterial cell powder, mixing the mixture, and then cooling and solidifying the mixture to pulverize and granulate.
  • coating with an enteric polymer compound involves dispersing the bacterial cell powder in a solution of a cellulose derivative such as hydroxypropylmethylcellulose phthalate and carboxymethylethylcellulose in a solvent such as alcohol, and then removing the solvent.
  • a cellulose derivative such as hydroxypropylmethylcellulose phthalate and carboxymethylethylcellulose
  • a known method such as pulverization may be used.
  • Fats and oils used in the water-in-oil type emulsion include soybean oil, palm oil, corn oil and the like, and surfactants include glycerin fatty acid ester, sorbin fatty acid ester, and propylene dalycol fatty acid ester.
  • the water-in-oil emulsification is performed by a known method such as emulsifying a water-soluble bacterial cell solution and a fat or oil to which a surfactant has been added by stirring or ultrasonic treatment.
  • Phospholipids used in ribosome preparations include saturated or unsaturated phosphodiesters such as egg yolk lecithin, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, and dioleoylphosphatidylcholine. And a phospholipid ⁇ lysolecithin whose hydrophilic group is choline, ethanolamine, serine, inositol, glycerol or the like. Of course, a plurality of the above phospholipids may be used in combination. Formulation is performed by a method known per se such as a reverse phase evaporation method and a sonication method.
  • the dosage may be 0.01 to 1000 mg (wet weight) of bacterial cells per 1 kg of the mammal's body weight, administered orally or nasally 1 to 10 times at intervals of 1 to 21 days.
  • a method for preventing mastitis by orally or nasally administering the agent for preventing mucositis for mastitis of the present invention to a mammal Further, a method for preventing mastitis by orally administering to a mammal by mixing the feed with the mucosal prophylactic agent for mastitis of the present invention and feeding the feed to the mammal is provided.
  • a 20-hour culture of S. aureus was inactivated with formalin and killed cells or lysozyme-treated cells were orally administered with cholera toxin as an adjuvant. Examination of the ability to protect against infection showed that it had an effect of protecting against infection.
  • the above immunizing antigen was centrifuged at 10,000 rpm at 4 for 10 minutes. After separation, the 1, 10 or 50 mg (wet weight) was suspended in 0.5 ral PBS, and 10 / zg cholera toxin (manufactured by Wako Pure Chemical Industries, Ltd.) was added as an adjuvant.
  • BALB / c female mice aged 8 to 10 weeks, weighing about 20 g, were orally administered twice at 14-day intervals. Study of infectious defenses against intramammary attack bacterial solution 0. lml containing 10 4 CFU of No. 46 strain of S. ⁇ ⁇ Reus cultured 1.
  • mice that were not immunized as a control group were also challenged under the same conditions. Necropsy was performed 48 hours after the challenge, and S. aureus was isolated from the mammary gland. Individuals who died by 48 hours after the challenge were necropsied as soon as possible and bacteria were collected from the mammary gland. Table 1 shows the mortality and the number of bacteria recovered from the mammary gland 48 hours after the challenge.
  • a PBS suspension of the immunizing antigen treated in the same manner as in Test Example 1 was prepared, and egg white lysozyme (Wako Pure Chemical Industries, Ltd.) at 1/10 (w / w) of the antigen (wet weight) was added. Thereafter, the cells were left standing at 37 for 30 minutes to perform lysis treatment. Thereafter, cholera toxin (manufactured by Wako Pure Chemical Industries, Ltd.) was added as an adjuvant, and immunization and challenge were performed in the same manner as in Test Example 1.
  • Table 2 shows the mortality and the number of bacteria recovered from the mammary gland 48 hours after the challenge. Table 2
  • the mean number of bacteria recovered from the mammary gland in the 50 mg immunized group was significantly higher at 4.1 and 4.5 l ogCFU / g in Test Examples 1 and 2, respectively than in the non-immunized group (Test Example 1: p ⁇ 0.05, Test example 2: p ⁇ 0.01) decreased.
  • S. aureus No. 46 which was used in Test Examples 1 and 2 above, was isolated from the milk of a pest with clinical mastitis and showed a high level of mastitis. 11 Deposited with the Yeast Research Institute (IF0) as IF016333 from October 28, 2011. Test Example 3: Infection protection and antibody response to intramammary gland attack by S. aureus in mice intranasally administered with S. aureus inactivated cells
  • mice Female BALB / c mice aged 8 to 10 weeks were tested and immunized intranasally or subcutaneously with inactivated S. aureus cells twice at 14 day intervals. Test mouse is the first exemption Immediately after the epidemic, they started living with the male, and then lived together for 7 days.
  • the No.46 strain of S. Aureusu cultured skim milk broth were inoculated into 10 5 to 10 6 CFU includes fourth mammary gland of the left and right bacterial dilutions 0. lml to 21 days after the second immunization. 48 hours after the intramammary gland challenge, S. aureus was collected from the mammary gland, and at the same time, serum was separated from the collected blood and the anti-S.
  • Aureus-specific IgA and IgG antibody titers were measured by ELISA.
  • the inactivated S. aureus cells used for intranasal administration were subjected to ultrasonic treatment at an oscillation frequency of 20 kHz, an output of 200 W, and for 30 minutes.
  • Table 3 Protective effect of infection against intramammary gland attack by S. aureus
  • n 0 No symptoms, 1: Mild weakness, 2: Moderate to severe weakness, 3: Death
  • intranasally immunized group (hereinafter referred to as “intranasally immunized group”) of the inactivated S. aureus inactivated bacterial cells treated with sonication was as follows:
  • subcutaneous immunized group (Hereinafter referred to as “subcutaneous immunized group”), which was lower than that of the non-immunized group.
  • the number of bacteria recovered from the mammary gland of the intranasal immunization group was almost the same as that of the subcutaneous immunization group, and was significantly (P 0.01) lower than that of the non-immunization group.
  • Serum IgG antibody in the intranasal immunization group was significantly higher than that in the subcutaneous immunization group.
  • Test example 4 Antibody response of immunized mice immunized intranasally with antigens (ovalbumin, ovalbumin) and adjuvant encapsulated in liposomal preparations
  • the antigens (ovalbumin, OVA) and adjuvants (cholera toxin, CT, and saponin) shown in Table 5 were encapsulated in ribosome preparations in Holstein breeding female females (weight around 150-200 kg). After intranasal administration and immunization, the antibody response of the mouse on day 21 was examined.
  • Table 5 shows the formulation of the test preparation, and Tables 6 to 9 show the results.
  • the preparation of the present invention is extremely practical since it has an excellent protective effect on mammalian mastitis infection and can be used by oral or nasal administration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Fodder In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des préparations d'administration par voie orale ou nasale destinées à la prévention des mastites de mammifères. Ces préparations contiennent un lysat cellulaire microbien contenant des cellules microbiennes inactivées de protéines ou de polysaccharides des parois extérieures microbiennes. L'invention concerne également de l'aliment pour bétail contenant un lysat cellulaire microbien contenant des cellules microbiennes inactivées de protéines ou de polysaccharides des parois extérieures microbiennes. L'invention permet ainsi la réalisation de produits vaccinaux muqueux contre la mastite de mammifères, administrables par voie orale ou nasale, et dont l'efficacité et la disponibilité pratique sont bien supérieures à celles des produits existants.
PCT/JP2000/007445 1999-10-29 2000-10-24 Preventifs muqueux contre la mastite WO2001032205A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU79564/00A AU7956400A (en) 1999-10-29 2000-10-24 Mucosal preventives for mastitis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP30911699A JP2003171291A (ja) 1999-10-29 1999-10-29 乳房炎用粘膜予防剤
JP11/309116 1999-10-29

Publications (1)

Publication Number Publication Date
WO2001032205A1 true WO2001032205A1 (fr) 2001-05-10

Family

ID=17989091

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2000/007445 WO2001032205A1 (fr) 1999-10-29 2000-10-24 Preventifs muqueux contre la mastite

Country Status (3)

Country Link
JP (1) JP2003171291A (fr)
AU (1) AU7956400A (fr)
WO (1) WO2001032205A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006090816A1 (fr) * 2005-02-25 2006-08-31 Mie University Procédé de fabrication de vaccin au liposome
WO2007091580A1 (fr) * 2006-02-07 2007-08-16 Nippon Biologicals, Inc. Nouveau transporteur de vaccin
JP2009286730A (ja) * 2008-05-29 2009-12-10 Nai Kk 新規乳房炎ワクチン
CN102294026A (zh) * 2010-11-17 2011-12-28 赤峰博恩药业有限公司 奶牛链球菌乳房炎灭活疫苗及其制备方法
CN102389568A (zh) * 2011-04-25 2012-03-28 通威股份有限公司 一种预防金鲳鱼溃疡病的疫苗
CN111387133A (zh) * 2020-02-25 2020-07-10 中国农业大学 一种肺炎克雷伯杆菌噬菌体抑制小鼠乳腺炎模型建立方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858073B2 (en) * 2004-08-17 2010-12-28 Hunter Technology Limited Oral killed vaccines and method for providing same
WO2015093545A1 (fr) * 2013-12-18 2015-06-25 旭化成株式会社 Procédé de détection de bactéries coliformes dans le lait
EP3085771B1 (fr) 2013-12-18 2020-01-22 Asahi Kasei Kabushiki Kaisha Procédé pour détecter des bactéries du genre streptococcus dans le lait
US10151751B2 (en) 2013-12-18 2018-12-11 Asahi Kasei Kabushiki Kaisha Method for detecting Staphylococcus contained in milk

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1182555A (en) * 1967-10-16 1970-02-25 Saphar Lab Ltd An Anti-Mastitis Vaccine
EP0038265A1 (fr) * 1980-04-14 1981-10-21 Merck & Co. Inc. Polysaccharides capsulaires de streptocoques du groupe B
JPH0356426A (ja) * 1989-07-24 1991-03-12 Gifu Meneki Kenkyusho:Kk ウシ乳房炎予防および治療用抗体含有材料
WO1995012410A1 (fr) * 1993-11-05 1995-05-11 Eli Lilly And Company Conception et production de vaccins
WO1995017211A1 (fr) * 1993-12-22 1995-06-29 Biocine S.P.A. Adjuvant non toxique pour les muqueuses

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1182555A (en) * 1967-10-16 1970-02-25 Saphar Lab Ltd An Anti-Mastitis Vaccine
EP0038265A1 (fr) * 1980-04-14 1981-10-21 Merck & Co. Inc. Polysaccharides capsulaires de streptocoques du groupe B
JPH0356426A (ja) * 1989-07-24 1991-03-12 Gifu Meneki Kenkyusho:Kk ウシ乳房炎予防および治療用抗体含有材料
WO1995012410A1 (fr) * 1993-11-05 1995-05-11 Eli Lilly And Company Conception et production de vaccins
WO1995017211A1 (fr) * 1993-12-22 1995-06-29 Biocine S.P.A. Adjuvant non toxique pour les muqueuses

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006090816A1 (fr) * 2005-02-25 2006-08-31 Mie University Procédé de fabrication de vaccin au liposome
WO2007091580A1 (fr) * 2006-02-07 2007-08-16 Nippon Biologicals, Inc. Nouveau transporteur de vaccin
JP2009286730A (ja) * 2008-05-29 2009-12-10 Nai Kk 新規乳房炎ワクチン
CN102294026A (zh) * 2010-11-17 2011-12-28 赤峰博恩药业有限公司 奶牛链球菌乳房炎灭活疫苗及其制备方法
CN102389568A (zh) * 2011-04-25 2012-03-28 通威股份有限公司 一种预防金鲳鱼溃疡病的疫苗
CN102389568B (zh) * 2011-04-25 2014-02-19 通威股份有限公司 一种预防金鲳鱼溃疡病的疫苗
CN111387133A (zh) * 2020-02-25 2020-07-10 中国农业大学 一种肺炎克雷伯杆菌噬菌体抑制小鼠乳腺炎模型建立方法
CN111387133B (zh) * 2020-02-25 2021-04-16 中国农业大学 一种肺炎克雷伯杆菌噬菌体抑制小鼠乳腺炎模型建立方法

Also Published As

Publication number Publication date
AU7956400A (en) 2001-05-14
JP2003171291A (ja) 2003-06-17

Similar Documents

Publication Publication Date Title
US20120135039A1 (en) Oral Vaccines for Producing Mucosal Immunity
US10806698B2 (en) Composition for oral delivery of bioactive agents
DE60122672T2 (de) Zusammensetzung zur intestinalen verabreichung
WO2001032205A1 (fr) Preventifs muqueux contre la mastite
KR20120061045A (ko) 오크로박트룸 인터미디움의 지질다당류 및 포유동물의 면역자극제로서 그의 용도
US20190174748A1 (en) Composition for delivery of active agents to an animal
JP2007538090A (ja) 伝達因子封入組成物および使用方法
TWI334355B (en) Method for preparing an orally administrable formulation for controlled release and orally administrable formulation
WO1995031184A1 (fr) Liberation de molecules bioactives
EP3768820B1 (fr) Francisella tularensis lyophilisation de souches vaccinales vivante contre
Suckow et al. Oral immunization of rabbits against Pasteurella multocida with an alginate microsphere delivery system
JP3649787B2 (ja) 魚類の腸球菌感染症用予防剤およびその用途
Piepers et al. Alternative approach to mastitis management–How to prevent and control mastitis without antibiotics?
JP2004043332A (ja) 経口用リポソーム製剤
CZ15898A3 (cs) Perorální přípravek k prevenci a léčbě infekčních gastroenteritid telat
KR101978865B1 (ko) Plga로 캡슐화된 불활성화 균체를 포함하는 백신 조성물 및 이의 제조방법
US6221386B1 (en) Use of virulence factors of pathogens to improve liposomal delivery of therapeutic agents
Bertók et al. Nomenclature and significance of innate/natural immune mechanisms and of species specific resistance
RU2815387C1 (ru) Штамм бактерий Corynebacterium pseudotuberculosis, предназначенный для получения моно- или поливалентных иммуногенных композиций, направленных на специфическую профилактику казеозного лимфаденита (псевдотуберкулеза) мелкого рогатого скота
US20230364213A1 (en) Method for lyophilizing live vaccine strains of francisella tularensis
CA2171369C (fr) Utilisation d'aggressines d'agents pathogenes permettant d'ameliorer l'administration liposomique d'antibiotiques et (ou) de vaccins
JP2000219637A (ja) エリシペロスリクス・ルシオパシエ抗原及びワクチン組成物
WO2024088138A1 (fr) Vaccin oral inactivé perméabilisé par une membrane plasmatique
US8524250B2 (en) Carrier
Șandru et al. An emerging episode of clostridial disease in imported dairy cattle.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase